Renal Pharmacology, Dosing, and Drug Safety — Advanced

Correct answer: Unfractionated heparin infusion with APTT monitoring. In significant renal impairment (CrCl <30 mL/min) low molecular weight heparins (LMWHs) such as enoxaparin accumulate, increasing bleeding risk; dosing regimens that rely on once-daily administration are inadequate to guarantee safe therapeutic exposure in severe AKI. Unfractionated heparin (UFH) has a shorter half-life, is not renally cleared to the same degree, and is rapidly reversible, making it the preferred initial agent while renal function is unstable or likely reversible. Fondaparinux is predominantly renally excreted and is contraindicated or used with extreme caution in severe renal impairment. Direct oral anticoagulants (eg rivaroxaban) are not appropriate in severe AKI because of reduced clearance, variable exposure and inability to rapidly reverse anticoagulation if needed. Reduced-frequency enoxaparin (eg once daily) does not reliably avoid accumulation in severe renal impairment and is not the preferred strategy in acute reversible AKI. Why alternatives are less appropriate: - A (enoxaparin 1 mg/kg q12h): standard therapeutic LMWH dosing commonly results in accumulation and bleeding in CrCl <30 mL/min. - B (enoxaparin 1 mg/kg once daily): reduced-frequency regimens may still cause accumulation and are not the safest choice when rapid reversal or titration may be needed. - D (fondaparinux): cleared renally and unsuitable in severe renal impairment. - E (rivaroxaban): DOACs have significant renal clearance and are generally avoided in acute severe AKI.

Correct answer: Give an IV loading dose (15–20 mg/kg) then measure trough and provide supplemental doses after each dialysis session guided by levels. Vancomycin is dialysable depending on dialysis membrane and modality (high-flux membranes remove significant drug). Best practice is to give an appropriate weight-based loading dose to reach therapeutic concentrations, then monitor serum concentrations and supplement dosing after dialysis sessions as required. Trough or AUC-guided monitoring informs re-dosing; in haemodialysis patients, supplementary post-dialysis dosing is commonly required.

Why alternatives are less appropriate:
- B (continuous infusion without loading/levels): continuous infusion without loading is likely to result in subtherapeutic initial exposure; dialysis alters clearance and therapeutic monitoring is required.
- C (low fixed doses without levels): fixed low dosing risks undertreatment and toxicity; monitoring is necessary.
- D (avoid vancomycin and use linezolid): linezolid is an alternative for some MRSA infections, but for bloodstream infections vancomycin remains a first-line agent in many cases; switching merely to avoid monitoring is not appropriate.
- E (oral vancomycin): oral vancomycin is not absorbed and is ineffective for systemic bacteraemia.

Correct answer: Meropenem 1 g IV every 8 hours. Continuous renal replacement therapy (CRRT) increases antibiotic clearance compared with non-dialysed patients; in critically ill patients on CRRT, meropenem dosing often needs to approximate standard or increased dosing (eg 1 g IV q8h) to achieve pharmacodynamic targets (time above MIC). Reduced doses (eg 500 mg q8h) or prolonged intervals risk underexposure. Continuous infusion can be used after a loading dose to optimise time-dependent killing, but should be used with an initial loading dose and therapeutic context; a single high daily dose is not appropriate for meropenem’s pharmacodynamics.

Why alternatives are less appropriate:
- A (500 mg q8h): may under-dose in CRRT and critical illness.
- B (1 g q12h): extended interval may not maintain time > MIC in severe infections on CRRT.
- C (2 g once daily): single daily dosing is inappropriate for time-dependent beta-lactams.
- D (continuous infusion without loading dose): continuous infusion can be effective but requires an initial loading dose to rapidly achieve therapeutic concentrations; without a loading dose, delays in reaching target exposures occur.

Correct answer: Inhibition of angiotensin II–mediated efferent arteriolar constriction reducing glomerular filtration pressure. ACE inhibitors (and ARBs) reduce angiotensin II activity, which normally constricts the efferent arteriole to maintain glomerular filtration pressure especially when renal perfusion is reduced (eg renal artery stenosis, volume depletion). Blocking this effect causes a fall in intraglomerular pressure with a rise in serum creatinine; a modest rise (<30%) may be acceptable, but larger rises suggest bilateral renal artery stenosis or severe renal hypoperfusion. Why alternatives are less appropriate: - A (direct tubular toxicity): ACE inhibitors are not typical causes of acute tubular necrosis. - B (prostanoid inhibition): that describes NSAID mechanism (inhibition of prostaglandin-mediated afferent vasodilatation), not ACE inhibitors. - D (immune interstitial nephritis): this is drug-induced by beta-lactams, NSAIDs, PPIs, etc., not a recognised common ACE inhibitor mechanism. - E (uric acid crystals): not a mechanism of ACE inhibitor–induced creatinine rise.

Under the dose-reduction criteria specified for this question, age 80 years or older and body weight 60 kg or less are two criteria for reducing apixaban to 2.5 mg twice daily. Dosing in dialysis is jurisdiction- and label-dependent, so local prescribing guidance must be followed; the key educational point is to apply the stated criteria consistently rather than assume either an absolute contraindication or an unchanged dose.

Correct answer: Stop lisinopril immediately and arrange imaging of the renal arteries. A rise in serum creatinine of >30% after commencing an ACE inhibitor suggests impaired ability to maintain intraglomerular pressure (eg bilateral renal artery stenosis). The recommended immediate action is to stop the ACE inhibitor and investigate for renal artery stenosis (eg duplex, CT angiography) rather than continue treatment. If the ACE inhibitor is responsible for the substantial decline in GFR, stopping it commonly leads to improved renal function.

Why alternatives are less appropriate:
- A (continue and monitor): a >30% rise is clinically significant and should prompt cessation and investigation.
- B (increase lisinopril dose): would likely worsen renal function.
- D (start IV fluids): unless there is evidence of hypovolaemia, aggressive fluids are not indicated and could cause harm.
- E (add loop diuretic): reducing intravascular volume will further reduce renal perfusion and is inappropriate.

Correct answer: Give intravenous calcium gluconate (or calcium chloride if central access) to stabilise the cardiac membrane. In hyperkalaemia with ECG changes, immediate membrane stabilisation with IV calcium is the priority because it rapidly reduces the risk of fatal arrhythmia, though it does not lower serum potassium. Other measures to shift potassium intracellularly (insulin with glucose, nebulised salbutamol, sodium bicarbonate if acidotic) should follow, and definitive removal (eg dialysis) should be arranged if necessary.

Why alternatives are less appropriate:
- B (oral sodium polystyrene sulfonate): onset is delayed and it's not appropriate as the immediate life-saving therapy.
- C (immediate haemodialysis without temporising): dialysis is definitive but arranging access and dialysis takes time; membrane stabilisation must be given immediately.
- D (oral magnesium oxide): magnesium is not the first-line treatment for ECG changes due to hyperkalaemia.
- E (dietary advice/outpatient follow-up): grossly inadequate and dangerously slow in the presence of ECG changes.

Correct answer: Proton-pump inhibitor (eg omeprazole). The presentation is typical for acute interstitial nephritis (AIN): recent drug exposure (commonly within days to weeks), rash, systemic symptoms, eosinophiluria/pyuria and rising creatinine. Proton-pump inhibitors are a well-recognised and increasingly common cause of AIN. NSAIDs can cause AIN but classically are more associated with nephrotic-range proteinuria and a different time course; beta-lactam antibiotics (eg penicillins) and rifampicin can also cause AIN, but in this vignette the timing and classic PPI association make PPI the most likely culprit.

Why alternatives are less appropriate:
- A (amoxicillin–clavulanate): can cause AIN but less likely given the recent PPI start and typical epidemiology.
- B (NSAIDs): can cause AIN but often with different features (eg nephrotic syndrome) and are a common cause but PPI is classically implicated in subacute AIN.
- C (rifampicin): can cause AIN but is usually associated with anti-tuberculous therapy history.
- D (allopurinol): can cause hypersensitivity syndromes including renal injury but less commonly presents with classic AIN histology compared with PPIs.

Aminoglycosides are concentration-dependent antibiotics with a post-antibiotic effect. In severe infection they may be given as a high initial dose with therapeutic drug monitoring, using measured concentrations and kidney function to adjust the dose and dosing interval. AUC-guided monitoring is preferred where available; peak/trough-based protocols remain used in some settings. Repeated unmonitored small doses risk accumulation and nephrotoxicity, while avoiding an indicated aminoglycoside or giving an unmonitored single dose risks treatment failure or toxicity.

Correct answer: Provide peri-procedural intravenous isotonic crystalloid (saline) and minimise contrast volume. Current guideline guidance emphasises adequate volume expansion with isotonic crystalloid (eg normal saline) for patients at increased risk of contrast-associated AKI, and minimising contrast dose and use of low-/iso-osmolar contrast media where possible. Routine use of N-acetylcysteine is not supported as standard prophylaxis by high-quality evidence and is no longer routinely recommended. Prophylactic haemodialysis to remove contrast is not recommended. Heparin and mannitol are not recommended prophylactic measures for contrast-associated AKI.

Why alternatives are less appropriate:
- A (oral N-acetylcysteine): evidence is inconsistent; not routinely recommended as a substitute for hydration.
- B (heparin prophylaxis): no evidence that anticoagulation prevents contrast nephropathy and it risks bleeding.
- C (prophylactic haemodialysis): studies do not support routine post-contrast dialysis to prevent AKI and it is impractical and risky.
- E (mannitol): not recommended and may be harmful.